future medical treatment includes the aggressive , widespread utilization of configurable microscopic medical payload delivery devices ( cmmpdd ) to deliver chemotherapy molecules directly to specific targeted cell types in the body . the configurable microscopic medical payload delivery device transporting chemotherapy molecules represents a very versatile medical treatment delivery device . cmmpdd is used to deliver chemotherapy molecules to a wide variety of cancer cells and inflammatory cells . utilizing cmmpdd to deliver chemotherapy molecules to cancer cells represents a new means to manage cancer . using cmmpdd to deliver chemotherapy molecules to inflammatory arthritis represents a new means to treat inflammatory arthritis . by delivering chemotherapy molecules directly to targeted cells and only to the targeted cells by virus - like transport devices , the configurable microscopic medical payload delivery devices represent a significant advancement over current chemotherapy treatment techniques in that this strategy avoids many of the unwanted side effects that conventional chemotherapy cause . for purposes of this text an ‘ external envelope ’ refers to the outermost covering of a virus or a virus - like transport device or a configurable microscopic medical payload delivery device . the external envelope may be comprised of a lipid layer , a lipid bilayer , the combination of a lipid layer affixed to a protein matrix or the combination of a lipid bilayer affixed to a protein matrix . a protein matrix is equivalent to a protein shell and may be referred to as a protein matrix shell . the terms protein matrix , protein shell , protein matrix shell are equivalent to the term capsid , where the term capsid is meant to represent ‘ a protein coat or shell of a virus particle , surrounding the nucleic acid or nucleoprotein core ’. the term ‘ particle ’ is equivalent to the term ‘ virion ’. for purposes of this text an ‘ internal shell ’ refers to a protein matrix shell nested inside the external envelope . the innermost protein matrix shell is termed the nucleocapsid . the proteins that comprise the nucleocapsid are termed capsid proteins . in the cavity created by the nucleocapsid , referred to as the center or core of the nucleocapsid , is where the payload of chemotherapy molecules is carried . for purposes of this text ‘ external probes ’ are molecular structures that are utilized to locate and engage cell - surface receptors on biologically active cells . external probes are generally comprised of a portion which is anchored or fixed in the external envelope and a second portion that extends out and away from the external envelope . the portion of the external probe that extends out and away from the external envelope is intended to make contact and engage a cell - surface receptor located on a biologically active cell . external probes may be comprised solely of a protein structure or an external probe may be a glycoprotein molecule . for purposes of this text ‘ glycoprotein molecule ’ refers to a molecule comprised of a carbohydrate region and a protein region . glycoprotein molecules that act as probes are generally anchored or fixed to a lipid layer utilizing the carbohydrate portion of the molecule as an anchor . the protein portion of the glycoprotein molecule which extends outward and away from the exterior envelope the glycoprotein has been affixed such that the protein region may function as a probe to locate and attach to the cell - surface receptor it was created to engage . the concept of configurable microscopic medical payload delivery devices is modeled after naturally existing viruses . configurable microscopic medical payload delivery devices in general are spherical in shape ; though other shapes may be used as function might warrant the use of a particular shape . the spherical configurable microscopic medical payload delivery devices are comprised of an exterior envelope and one or more inner nested protein shells . a quantity of exterior protein structure probes and / or glycoprotein probes are anchored in the exterior lipid envelope and a portion extends out and away from the exterior lipid envelope . nesting of protein shells refers to progressively smaller diameter shells fitting snugly inside protein shells of a larger diameter . inside the inner most protein shell , referred to as the nucleocapsid , is a cavity referred to as the core of the device . the core of the device is the space where the medically therapeutic payload the device carries is located . the payload of the device is comprised of chemotherapy molecules . configurable microscopic medical payload delivery devices ( cmmpdd ) target specific types of cells in the body . configurable microscopic medical payload delivery devices engage specific types of cells by the configuration of probes affixed to the exterior envelope of the cmmpdd . by fixing specific probes to the exterior envelope of the cmmpdd , these probes intended to engage and attach only to specific cell - surface receptors located on certain cell types in the body , the cmmpdd will deliver its payload to only those cell types that express compatible and engagable specific cell - surface receptors . in a similar fashion where the exterior probes of a naturally occurring virus engage specific cell - surface receptors present on the surface of the virus &# 39 ; s host cell and only the designated host cell , the cmmpdd &# 39 ; s exterior probes are configured to engage cell - surface receptors on a specific type of target cell and only those cells . in this manner , the payload of chemotherapy drug molecules carried by cmmpdd will be delivered only to specific types of cells in the body . the configuration of the exterior probes on the surface of a cmmpdd will vary as needed so as to effect the cmmpdd delivery of chemotherapy drug payloads to the specific cell types as needed to effect a particular predetermined medical treatment . the size of configurable microscopic medical payload delivery devices is dependent upon the diameter of the inner protein matrix shells and this is dictated by the volume size of the payload the cmmpdd is required to carry and deliver to a target cell . the diameter of each inner protein matrix shell is governed by the number of protein molecules utilized to construct the protein matrix shell at the time the protein matrix shell is generated . increasing the number of proteins that comprise a protein matrix shell , increases the diameter of the protein matrix shell . when applicable an external lipid envelope wraps around and covers the outermost protein matrix shell . the larger the volume of the core of the cmmpdd , the greater the physical size payload the cmmpdd is able to carry . the size of the configurable microscopic medical payload delivery device is to be the size of cell ( approximately 10 − 4 m in diameter ) or less , generally detectable by a light microscope or , as needed , an electron microscope . the size of the cmmpdd is not to be too large such that it would generate a burden to the body by damaging organ tissues through clogging blood vessels or glomeruli in the kidneys . the dimensions of each type of cmmpdd are to be tailored to the mission of the cmmpdd , which takes into account factors such as the type of target cell , the size of the payload that is to be delivered to the target cells and the length of time the cmmpdd may have to engage the target cell . being enveloped in an external lipid layer , configurable microscopic medical payload delivery devices possess the advantage of having their exterior appear similar to the plasma membrane that acts as an outside covering for the cells that comprise the body . by appearing similar to existing plasma membranes , the cmmpdds appear similar to naturally occurring structures found in the body . cmmpdd &# 39 ; s are afforded the capability to avoid detection by a body &# 39 ; s immune system because the exterior of the cmmpdd mimics the cells comprising the body and the surveillance elements of the immune system find it difficult to discern between the cmmpdd and naturally occurring cells comprising the body . to carry out the process of manufacturing a configurable microscopic medical payload delivery device , a primitive cell such as a stem cell is selected . the reason for utilizing primitive cells such as stems cells as the host cell , is that the cmmpdd acquires its outer envelope from the host cell and the more primitive the host cell , the fewer in number the identifying protein markers are present on the surface of the cmmpdd . the fewer the identifying surface proteins present on the outer envelope of the cmmpdd , the less likely a body &# 39 ; s immune system will identify the cmmpdd as an intruder and therefore less likely the body &# 39 ; s immune system will react to the presence of the cmmpdd and reject the cmmpdd by attacking and neutralizing the cmmpdd . stem cells used as host cells to manufacture quantities of cmmpdd product are selected per histocompatibility markers present on their surface . certain histocompatibility markers present on the surface of the final cmmpdd product will be less likely to cause a reaction in a specific patient based on the genetic profile of the patient &# 39 ; s histocompatibility markers . a similar histocompatibility match is done when donor organs are selected to be given to recipients to avoid rejection of the donor organ by the recipient &# 39 ; s immune system . the selected stem cells used to manufacture configurable microscopic medical payload delivery devices goes through several steps of maturation before it is capable of generating therapeutic cmmpdd product . messenger rna would be inserted into the host stem cell that would code for the general physical outer structures of the cmmpdd . messenger rna would be inserted into the host that would generate surface probes that would target the cell - surface receptors on specific target cell types . messenger rna would be inserted into the host that would be used to generate the payload of chemotherapy molecules or the chemotherapy molecules are introduced into the cmmpdd post production of the cmmpdd based on the size and complexity of the chemotherapy molecules . similar to how copies of a naturally occurring virus , such as the hepatitis c virus or hiv , are produced , assembled and released from a host cell , copies of the cmmpdd would be produced , assembled and released from a host cell . once released from the stem cell functioning as a de facto host cell , the copies of the cmmpdd would be collected , then pooled together to produce a therapeutic dose that results in a medically beneficial effect . the stem cells used as host cells are suspended in a broth of nutrients and are kept at an optimum temperature to govern the rate of production of the cmmpdd product . similar to the natural production of the hepatitis c virus , the configurable microscopic medical payload delivery devices ‘ production genome ’ is introduced into the host stem cells . the configurable microscopic medical payload delivery devices production genome carries genetic instructions to cause the host cells to manufacture the configurable microscopic medical payload delivery devices &# 39 ; outer protein wall , the inner protein matrixes , the surface probes the configurable microscopic medical payload delivery device is to have affixed to its outer envelope , the chemotherapy molecules the configurable microscopic medical payload delivery devices are to carry , and the instructions to assemble the various pieces into the final form of the configurable microscopic medical payload delivery devices along with the instructions to activate the budding process . the resultant configurable microscopic medical payload delivery devices are collected from the nutrient broth surrounding the host cells and placed together into doses to be used as a treatment for a medical disease . the ‘ production genome ’ are an array of messenger rnas that are directly translated by the host cell &# 39 ; s ribosomes . the production genome dictates the characteristics of the final version of the cmmpdd that buds from the host stem cell and is released and is to be utilized as a medical treatment . the production genome is specifically tailored to code for the surface probes that will seek and engage a specific type of target cell . the production genome also carries the instructions to code for the production of the type of chemotherapy molecules to be delivered to the specific type of target cell . the ‘ production genome ’ varies depending upon the configuration of the cmmpdd and the type of chemotherapy molecules the cmmpdd will transport to effect a specific medical treatment in a specific type of cell . the configurable microscopic medical payload delivery device transporting chemotherapy molecules represents a very versatile medical treatment delivery device . cmmpdd is used to deliver chemotherapy molecules to a wide variety of cancer cells and inflammatory cells . utilizing cmmpdd to deliver chemotherapy molecules to cancer cells represents a new means to manage cancer . using cmmpdd to deliver chemotherapy molecules to inflammatory arthritis represents a new means to treat inflammatory arthritis . as an example of this method , to treat breast cancer utilizing configurable microscopic medical payload delivery devices to deliver to breast cells chemotherapy such as the antimetabolite methotrexate , the following production process is followed in the lab : ( 1 ) human stem cells are selected . ( 2 ) into the selected stem cells is placed the production genome constructed , in this case , specifically as a means to treat breast cancer . the rna production genome contains genetic instructions to cause the host stem cells to manufacture the configurable microscopic medical payload delivery devices &# 39 ; outer protein wall , the inner protein matrix , surface probes to include glycoprotein probes that engage estrogen cell - surface receptors present on the surface of breast cells , and the payload of chemotherapy molecules ; and the biologic instructions to assemble the components into the final form of the configurable microscopic medical payload delivery devices ; and the biologic instructions to activate the budding process . ( 3 ) upon insertion of the rna production genome dedicated to producing a configurable microscopic medical payload delivery devices to transport chemotherapy molecules , into the host stem cells , host stem cells respond by ( i ) simultaneously translating the different segments of the rna production genome to produce the proteins that comprise the exterior protein wall , the inner protein matrix shell molecules , the surface probes to seek out and engage breast cells , the chemotherapy molecules , and ( ii ) decoding the rna instructions to assemble the components into the configurable microscopic medical payload delivery devices . ( 4 ) upon assembly , the configurable microscopic medical payload delivery devices bud through the cell membrane of the host stem cell . ( 5 ) at the time of the budding process , the configurable microscopic medical payload delivery devices acquire an outside envelope wrapped over the outer protein shell , this outer envelope comprised of a portion of the plasma membrane from the host stem cell as the configurable microscopic medical payload delivery devices exit the host cell . ( 6 ) in some cases dependent upon the treatment application and how tightly packed the configurable microscopic medical payload delivery devices need to be packed with chemotherapy molecules , such chemotherapy molecules may be present in the nutrient broth and diffuse into the configurable microscopic medical payload delivery devices . ( 7 ) the resultant configurable microscopic medical payload delivery devices are collected from the nutrient broth surrounding the host stem cells . ( 8 ) the configurable microscopic medical payload delivery devices are washed in sterile solvent to remove contaminants . ( 9 ) the configurable microscopic medical payload delivery devices are removed from the sterile solvent and suspended in a hypoallergenic liquid medium . ( 10 ) the configurable microscopic medical payload delivery devices are separated into individual quantities to facilitate storage and delivery to physicians and patients . ( 11 ) the configurable microscopic medical payload delivery devices transported in the hypoallergenic liquid medium is administered to a patient with a diagnosis of breast cancer per injection in a dose that is tailored to receiving patient &# 39 ; s severity of breast cancer . ( 12 ) upon being injected into the body , the configurable microscopic medical payload delivery devices migrate to the breast tissues by means of the patient &# 39 ; s blood stream . ( 13 ) upon the configurable microscopic medical payload delivery devices reaching the breast cells , the configurable microscopic medical payload delivery devices engage the cell - surface receptors located on the breast cells and insert the payload they carry into the breast cells . the payload , in this case being the chemotherapy methotrexate . methotrexate molecules inhibit dihydrofolate reductase and therefore prevents breast cells synthesizing nucleic acids , therefore prevents cell division , which prevents the cancer cells from replicating but does not interfere with normal breast cells . in a similar fashion , configurable microscopic medical payload delivery devices can be fashioned to deliver a payload of a specific chemotherapy molecule to any type of cancer cell or inflammatory cell in the body . different cell types express different cell - surface markers on the exterior of their plasma membrane . the differing configurations of cell - surface markers on differing types of cells distinguish one cell type from another cell type . by configuring the exterior probes that extend from the surface of the configurable microscopic medical payload delivery device to seek out and engage specific cell - surface receptors present on normal cells and cancer cells payloads of chemotherapy can be delivered to specific cells in the body . rheumatoid arthritis is an inflammatory disease affecting millions of people worldwide . the chemotherapy drug methotrexate has been used for over twenty years , and is used quite extensively as a treatment of rheumatoid arthritis . oral and injectable forms of the methotrexate are used to suppress the growth and cell division of synovial tissues . oral and injectable methotrexate causes many unwanted side effects . utilizing configurable microscopic medical payload delivery devices to deliver methotrexate molecules specifically to synovial cells and only to synovial cells , increases the efficacy of methotrexate and reduces or eliminates the unwanted side effects of methotrexate . accordingly , the reader will see that the configurable microscopic medical payload delivery device to deliver chemotherapy molecules to specific targeted cell types provides advantages over existing art by : ( 1 ) being a delivery device that seeks out specific types of cells , ( 2 ) by being a delivery device that is versatile enough to deliver a variety of potential chemotherapy molecules to accomplish various medical treatments , ( 3 ) by being a device that delivers chemotherapy molecules only to targeted cells , thus avoiding unwanted side effects that current chemotherapy causes , and ( 4 ) by being a delivery device constructed with a surface envelope that will avoid detection by the innate immune system and the adaptable immune system so as not to activate either immune system to its presence ; for these reasons this represents a new and unique medical delivery device that has never before been recognized nor appreciated by those skilled in the art . although the description above contains specificities , these should not be construed as limiting the scope of the invention but as merely providing illustrations of some of the presently preferred embodiments of the invention . thus the scope of the invention should be determined by the appended claims and their legal equivalents , rather than by the examples given . the terms and expressions which are employed here are used as terms of description and are not of limitation and there is no intention , in the use of terms and expressions , of excluding equivalents of the features presented , and described , or portions thereof , it being recognized that various modifications are possible in the scope of the invention or process as claimed .
the innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport means to deliver chemotherapy molecules to specific cell types in the body . utilizing probes present on the exterior of the transport device , transport device locates specific target cell types in the body . once a specific target cell type has been encountered , the configurable microscopic medical payload delivery device inserts its payload of chemotherapy molecules into the target cell type . by delivering chemotherapy molecules into specific cells , the growth of the specific cells can be stifled . delivering chemotherapy molecules into specific cancer cells inhibits the rate of growth and rate of cell reproduction of the cancer cells . utilizing configurable microscopic medical payload delivery devices to insert chemotherapy into targeted cancer cells or inflammatory cells effectively manages cancer , inflammatory arthritis and other inflammatory conditions , while preventing unwanted side effects .